(1R,3S,5R)-2-(tert-Butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid

Catalog No. :
ACUJPC631
CAS No. :
197142-34-0
Molecular Formula :
C11H17NO4
Molecular Weight :
227.26

IUPAC Name:(1R,3S,5R)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid

(1R,3S,5R)-2-(tert-Butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$130.00Login to see priceIn stockInquiry
5g97%$483.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(1R,3S,5R)-2-(tert-Butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid
IUPAC Name(1R,3S,5R)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid
MDL No.MFCD08691405
Molecular FormulaC11H17NO4
Molecular Weight227.26
SMILESO=C([C@H]1N(C(OC(C)(C)C)=O)[C@]2([H])C[C@]2([H])C1)O
InChI KeyVXIIZQXOIDYWBS-PRJMDXOYSA-N
Synonym197142-34-0 | (1R,3S,5R)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid | (1R,3S,5R)-2-[(tert-butoxy)carbonyl]-2-azabicyclo[3.1.0]hexane-3-carboxylic acid | (1r,3s,5r)-2-boc-2-azabicyclo[3.1.0]hexane-3-carboxylic acid | (1R,3S,5R)-2-(tert-But
CAS No.197142-34-0
PubChem CID11020613

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACUJPC631 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUJPC631 route product structure diagram
    ACUJPC631197142-34-0 In Stock
Inquiry

2. ACUJPC631 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCVYH684 route compound structure diagram
    ACCVYH684197142-33-9 In Stock
  2. Then
  3. ACUJPC631 route product structure diagram
    ACUJPC631197142-34-0 In Stock
Inquiry

Comments (0)